Processa Pharmaceuticals, Inc.
PCSA
$0.2294
-$0.0059-2.51%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -15.65% | -31.31% | -47.11% | -55.64% | -35.32% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.19% | -20.30% | -43.63% | -51.92% | -43.44% |
| Operating Income | -5.19% | 20.30% | 43.63% | 51.92% | 43.44% |
| Income Before Tax | -6.55% | 46.95% | 60.17% | 65.18% | 59.45% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -6.55% | 46.95% | 60.17% | 65.18% | 59.45% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -6.55% | 46.95% | 60.17% | 65.18% | 59.45% |
| EBIT | -5.19% | 20.30% | 43.63% | 51.92% | 43.44% |
| EBITDA | -8.93% | 16.98% | 41.14% | 51.03% | 43.18% |
| EPS Basic | 55.00% | 78.73% | 81.32% | 81.07% | 74.19% |
| Normalized Basic EPS | 55.00% | 65.30% | 73.02% | 74.23% | 65.07% |
| EPS Diluted | 55.00% | 78.73% | 81.32% | 81.07% | 74.19% |
| Normalized Diluted EPS | 55.00% | 65.30% | 73.02% | 74.23% | 65.07% |
| Average Basic Shares Outstanding | 133.33% | 117.53% | 99.30% | 84.15% | 62.77% |
| Average Diluted Shares Outstanding | 133.33% | 117.53% | 99.30% | 84.15% | 62.77% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |